Early trial of linvoseltamab shows promise for newly diagnosed multiple myeloma patients | ASH 2025

Robert Orlowski, M.D., Ph.D., of the MD Anderson Cancer Center shared early results from the LINKER-MM1 trial with Managed Healthcare Executive, which is testing linvoseltamab in people newly diagnosed with multiple myeloma. He said the trial design is special because it uses a step-up dosing schedule to help keep patients safe while still giving strong treatment.

Orlowski shared early findings showing good response rates so far. He also noted the main side effects seen in phase 1, such as cytokine release syndrome, low blood counts, and infections. These side effects were mostly manageable. He said the safety results in this early trial look similar to what has already been seen in studies of linvoseltamab for patients whose myeloma has come back or not responded to treatment.